Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery

Phase 2 Completed 20 enrolled University College, London Cancer Research UK · collab Hoffmann-La Roche · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy, toxicity and feasibility of FOLFOX/ bevacizumab and FOLFOXIRI/ bevacizumab neoadjuvant therapy in poor prognosis rectal cancer as defined by MRI.

Timeline

Start: 2013-04
Primary completion: 2018-01-10
Completion: 2019-02-14

Publications

Glynne-Jones R, Hava N, Goh V, Bosompem S, Bridgewater J, Chau I, Gaya A, Wasan H, Moran B, Melcher L, MacDonald A, Osborne M, Beare S, Jitlal M, Lopes A, Hall M, West N, Quirke P, Wong WL, Harrison M; Bacchus investigators. Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum. BMC Cancer. 2015 Oct 23;15:764. doi: 10.1186/s12885-015-1764-1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Irinotecan	Small molecule	165 mg/m2	Intravenous
Background	Bevacizumab	Monoclonal antibody	5 mg/kg	Intravenous
Background	Oxaliplatin	Small molecule	85 mg/m2	Intravenous
Background	fluorouracil	Small molecule	3200 mg/m2	Intravenous

Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery

Summary

Timeline

Publications

Drugs

Indications